{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T18:21:45Z","timestamp":1794680505314,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.lanepe.2026.101884","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:35:33Z","timestamp":1790696133000},"page":"101884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical trials on medicinal products in the EU\/EEA, 2013\u20132025: a cross-sectional analysis of CTIS and EudraCT data"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-4382","authenticated-orcid":false,"given":"Tiago","family":"Machado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0329-2603","authenticated-orcid":false,"given":"IJsbrand","family":"den Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2087-8334","authenticated-orcid":false,"given":"Felix","family":"Bindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Marcelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"van Wyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Zanoletty Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Santos Ivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Arlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101884_bib3","series-title":"Regulation (EU) 2021\/522 of the European Parliament and of the Council of 24 March 2021 Establishing a Programme for the Union\u2019s Action in the Field of Health (\u2018EU4Health Programme\u2019) for the Period 2021-2027, and Repealing Regulation (EU) No 282\/2014","first-page":"1","year":"2021"},{"key":"10.1016\/j.lanepe.2026.101884_bib10","series-title":"Revised CTIS Transparency Rules","year":"2023"},{"key":"10.1016\/j.lanepe.2026.101884_bib11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/d41573-024-00085-5","article-title":"Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape","volume":"23","author":"Capone","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lanepe.2026.101884_bib14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1017\/rsm.2025.10061","article-title":"Aggregating and analysing clinical trials data from multiple public registers using R package ctrdata","volume":"17","author":"Herold","year":"2026","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.lanepe.2026.101884_bib15","series-title":"Global Trends in R&D 2025: Progress in Recapturing Momentum in Biopharma Innovation","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101884_bib16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/s41587-024-02357-2","article-title":"Biotech financing: darkest before the dawn","volume":"42","author":"Senior","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.lanepe.2026.101884_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clinthera.2021.12.010","article-title":"Real-world data in the postapproval setting as applied by the EMA and the US FDA","volume":"44","author":"Mofid","year":"2022","journal-title":"Clin Ther"},{"key":"10.1016\/j.lanepe.2026.101884_bib18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/d41573-025-00185-w","article-title":"Innovative antibody therapeutic development in China compared with the USA and Europe","volume":"25","author":"Crescioli","year":"2026","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lanepe.2026.101884_bib19","article-title":"Globalisation of industry-sponsored clinical trials for breast, lung and colon cancer research: trends, threats and opportunities","volume":"2","author":"Payedimarri","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.lanepe.2026.101884_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2025.111791","article-title":"Registered clinical trial trends evolved differently in East Asia vs the United States during 2014\u20132023","volume":"183","author":"Lee","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.lanepe.2026.101884_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1228148","article-title":"The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs","volume":"14","author":"Namiot","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101884_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015579","article-title":"Development in the number of clinical trial applications in Western Europe from 2007 to 2015: retrospective study of data from national competent authorities","volume":"7","author":"Dombernowsky","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2026.101884_bib23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1745-6215-13-53","article-title":"Impact assessment of the European Clinical Trials Directive: a longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries","volume":"13","author":"Hartmann","year":"2012","journal-title":"Trials"},{"key":"10.1016\/j.lanepe.2026.101884_bib24","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101884_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s13063-022-06713-y","article-title":"Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases","volume":"23","author":"del \u00c1lamo","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.lanepe.2026.101884_bib28","year":"2025"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T17:42:30Z","timestamp":1794678150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":16,"alternative-id":["S2666776226002966"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101884","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials on medicinal products in the EU\/EEA, 2013\u20132025: a cross-sectional analysis of CTIS and EudraCT data","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101884"}}